Cost Effectiveness of tac versus fac in Adjuvant Treatment of Node-Positive Breast Cancer | Zendy

Nicole Mittmann | Zendy; S. Verma | Zendy; Marika Koo | Zendy; Karine Alloul | Zendy; Maureen Trudeau | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cost Effectiveness of tac versus fac in Adjuvant Treatment of Node-Positive Breast Cancer

Author(s) -

Nicole Mittmann,

S. Verma,

Marika Koo,

Karine Alloul,

Maureen Trudeau

Publication year - 2010

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.v17i1.445

Subject(s) - medicine , febrile neutropenia , docetaxel , breast cancer , oncology , cyclophosphamide , adverse effect , neutropenia , cost effectiveness , chemotherapy , cancer , risk analysis (engineering)

This economic analysis aimed to determine, from the perspective of a Canadian provincial government payer, the cost-effectiveness of docetaxel (Taxotere: Sanofi-Aventis, Laval, QC) in combination with doxorubicin and cyclophosphamide (TAC) compared with 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) following primary surgery for breast cancer in women with operable, axillary lymph node-positive breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research